|
KMID : 0371420170920050331
|
|
Annals of Surgical Treatment and Research
2017 Volume.92 No. 5 p.331 ~ p.339
|
|
|
Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
|
|
Park Hyung-Seok
Park Seo-Jin
Kim Jee-Ye
Kim Sang-Hwa
Ryu Jae-Gyu
Sohn Joo-Hyuk
Park Se-Ho
Kim Gun-Min
Hwang In-Sik
Choi Jong-Rak
Kim Seung-Il
|
|
|
Abstract
|
|
|
Purpose: We evaluated the clinical role of rapid next-generation sequencing (NGS) for identifying BRCA1/2 mutations compared to traditional Sanger sequencing.
Methods: Twenty-four paired samples from 12 patients were analyzed in this prospective study to compare the performance of NGS to the Sanger method. Both NGS and Sanger sequencing were performed in 2 different laboratories using blood samples from patients with breast cancer. We then analyzed the accuracy of NGS in terms of variant calling and determining concordance rates of BRCA1/2 mutation detection.
Results: The overall concordance rate of BRCA1/2 mutation identification was 100%. Variants of unknown significance (VUS) were reported in two cases of BRCA1 and 3 cases of BRCA2 after Sanger sequencing, whereas NGS reported only 1 case of BRCA1 VUS, likely due to differences in reference databases used for mutation identification. The median turnaround time of Sanger sequencing was 22 days (range, 14?26 days), while the median time of NGS was only 6 days (range, 3?21 days).
Conclusion: NGS yielded comparably accurate results to Sanger sequencing and in a much shorter time with respect to BRCA1/2 mutation identification. The shorter turnaround time and higher accuracy of NGS may help clinicians make more timely and informed decisions regarding surgery or neoadjuvant chemotherapy in patients with breast cancer.
|
|
|
KEYWORD
|
|
|
BRCA1, BRCA2, Breast neoplasms, High-throughput nucleotide sequencing
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|